About Prutis

Prutis (Nintedanib) is a tyrosine kinase inhibitor with antifibrotic properties.

It works by blocking pathways that drive lung fibrosis, helping preserve lung function and slow disease progression.

Approved Indications
  • Idiopathic Pulmonary Fibrosis (IPF)
  • Chronic Fibrosing ILDs with a progressive phenotype
  • Systemic Sclerosis-Associated ILD (SSc-ILD)
Product Image

Our Products Range

Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of
classical Latin literature from 45 BC, making it over 2000 years old.

Product Image
Prutis 100

Nintedanib Soft Gelatin Capsules - 100 mg

Product Image
Prutis 150

Nintedanib Soft Gelatin Capsules - 150 mg

Prescribed as per physician guidance based on patient condition.

Product Image

Benefits & Clinical
Evidence

  • Slowing decline in lung function (measured by FVC)
  • Reduces risk of ILD progression events
  • Clinically proven in global trials (INPULSIS, INBUILD, INJOURNEY)
  • Long-term safety established (>4 years of follow-up)
Product Image

Why Early Treatment
Matters

Lung scarring in ILD is irreversible once established.

  • Early diagnosis through HRCT and PFTs allows timely intervention
  • Managing progression early can preserve daily activities and improve quality of life

Frequently Asked Questions

Is Prutis safe during pregnancy or breastfeeding?

ILD is a long-term condition. Consistent treatment helps slow progression.

Read More FAQs
Disclaimer

Prutis (Nintedanib 100 mg/150 mg Soft Gelatin Capsules) is a prescription medicine to be used under the supervision of a registered medical practitioner. Information provided here is for educational purposes only and not a substitute for professional medical advice.